Stocks Site Search :

Buy Microsoft Products with us and Save upto 60%

Quarterly Results/Financial Ratios/Stock News

WidgetBucks - Trend Watch - WidgetBucks.com
Showing posts with label Sun Pharma. Show all posts
Showing posts with label Sun Pharma. Show all posts

Thursday, February 28, 2008

Sun Pharma challenges J&J`s drug patent

Mumbai-based Sun Pharmaceuticals has filed a post-grant opposition with the Mumbai patent office against a product patent granted to the extended release version of Johnson and Johnson’s (J&J) blockbuster drug Risperdal, used in the treatment of psychological disorders and schizophrenia.

Risperdal, with the molecular name risperidone, is the second-largest selling drug of Johnson and Johnson with over $4.5 billion worldwide sales in tablet, injection, syrup and orally dispensable forms. It is also one among the largest selling psychiatric drugs, according to sources.

Sun Pharma has been marketing a generic version of this drug for the last few years in India under the brand name Sizodone, according to company sources.

The patent on Risperdal, granted in February 1986, will expire in the US on June 29, 2008. The Indian patent was for an extended release version and this had not been patented in the US, said patent experts having knowledge of the development.

Patent wars
Swiss drug maker Roche’s anti-cancer drug, Pegasys, was given a patent in India in 2006 and this was challenged by Wockhardt and a Mumbai-based non-governmental organisation, Sankalp.

Generic drugmaker Cipla is battling in the Supreme Court to revoke a patent granted in February 2007 to Roche’s cancer drug Tarceva.

Another patent granted to Roche’s anti-HIV drug, Valganciclovir, is also being challenged in the court by Lawyers Collective, a Mumbai-based NGO, and Cipla.

According to the Indian Patent Act, which was amended in 2005, a product patent that bars other companies from copying the drug for generics, can be challenged within one year.

The Mumbai patent office granted a patent to Janssen Pharmaceutica, a group company of Johnson and Johnson, on July 20, 2007, with patent number 208191, against its mail box application number 188AL/1995. The patent related to sustained-release particles of risperidone, said sources. Company sources declined to reveal the sales figures for the drug in India.

“We don’t comment on litigations and patent-related issues as a matter of policy,” said a Sun Pharma spokesperson.

Interestingly, Dr Reddy’s Laboratories and US-based Mylan Laboratories were among the first to challenge the patent on Risperdal in the US, where the drug has sales of over $2 billion, said sources.

“Since the product patent regime was introduced in India in 2005, we estimate that more than 150 product patents have been granted and over 90 per cent of this is for multinational pharmaceutical companies. So far, very few products have been opposed by Indian companies, according to our knowledge,” said Varun Chonkar, a patent expert.

He said the Indian patent office was yet to officially announce data on the number of patents granted and challenged in India.

Posted by Srivatsan at 5:32 PM 0 comments

Labels:

Wednesday, January 30, 2008

Q3 Results Update - Part 1

Bajaj Auto Q3 consolidated net down 17%

Bajaj Auto today reported a 16.60% decline in consolidated net profit at Rs 273.82 crore for the quarter ended December 31, 2007 when compared with Rs 328.35 crore in Q3FY07.

According to a release issued to the Bombay Stock Exchange, net sales and income from operations declined to Rs 2,633.26 crore for the quarter ended December 31, 2007 from Rs 2,696.03 crore for the quarter ended December 31, 2006.

The company, on a standalone basis, reported a 5.32% decline in net profit at Rs 326.81 crore for the quarter ended December 31, 2007 as against Rs 345.19 crore in Q3FY07.

Total income declined from Rs 2,729.18 crore for the quarter ended December 31, 2006 to Rs 2,680.35 crore for the quarter ended December 31, 2007.

Sun Pharma Q3 net up 60%

Sun Pharmaceutical Industries today reported a 60.09% increase in net profit after minority interest at Rs 318.35 crore for the quarter ended December 31, 2007 as compared to Rs 198.85 crore in Q3FY07.

According to a release to the BSE, the company's total income has increased to Rs 821.88 crore for the quarter ended December 31, 2007 from Rs 603.59 crore for the quarter ended December 31, 2006 .

Mahindra & Mahindra PAT up 68%

Mahindra and Mahindra today announced a 67.63% increase in profit after tax (PAT) on a stand-alone basis at Rs 405.15 crore for the quarter ended December 31, 2007 as against Rs 241.68 crore in Q3FY07.

According to a release to the BSE, the company's total income increased to Rs 2,980.25 crore for the quarter ended December 31, 2007 from Rs 2,617.30 crore for the quarter ended December 31, 2006

Aurobindo Pharma net dips 8%

Hyderabad-based generic pharmaceuticals and active pharmaceutical ingredients (APIs) manufacturer, Aurobindo Pharma, witnessed a slight decline of 8% in net profit at Rs 55.25 crore for quarter ended December 31, 2007 when compared with Rs 60.12 crore in Q3FY07.

The company's total income grew 7.35% to Rs 549.52 crore for the quarter ended December 31, 2007 from Rs 511.86 crore for the quarter ended December 31, 2006.

Tata Chemicals Q3 PAT dips 42%

Tata Chemicals today announced a 41.55% dip in net profit after tax (PAT) of Rs 91.09 crore for the quarter ended December 31, 2007 as compared to Rs 155.85 crore in Q3FY07.

According to a release to the Bombay Stock Exchange, the company's total income has decreased to Rs 1712.67 crore for the quarter ended December 31, 2007 from Rs 1,793.70 crore for the quarter ended December 31, 2006 .

The company has, however, on a stand-alone basis, posted a PAT increase of 7.45% at Rs 125.48 crore for the quarter ended December 31, 2007 when compared with Rs 116.77 crore in Q3FY07.

The company's total income has decreased to Rs 1,236.52 crore for the quarter ended December 31, 2007 from Rs 1,318.81 crore for the quarter ended December 31, 2006 .

Posted by Srivatsan at 5:14 AM 0 comments

Labels: , , , ,

Subscribe to: Posts (Atom)

Understanding Short Term Trading

Before I begin, this blog is not for intraday traders. My definition of short term implies duration of around 2 to 3 months.

Short Term stock picking is no rocket science, but rather a visual interpretation of technical charts. A basic moving average on a time frame chart will show the direction of the securities movement.

Moving averages is a mathematical results calculated by averaging a number of past data points. Moving averages (MA) in it's basic form is calculated by taking the arithmetic mean of a given set of values on a rolling window of timeframe. Once the value of MA has been calculated, they are plotted onto a chart and then connected to create a moving average line. Typical moving averages used for short term trading are 50 MA and 100 MA.

Types of Moving Averages

1) Simple Moving Average (SMA)

SMA is calculated by taking the arithmetic mean of a given set of values on a rolling window of timeframe. The usefulness of the SMA is limited because each point in the data series is weighted the same, regardless of where it occurs in the sequence. Critics argue that the most recent data is more significant than the older data and should have a greater influence on the final result.

2) Exponential Moving Average (EMA)

EMA overcomes the limits of SMA, where more weight is given to the recent prices in an attempt to make it more responsive to new information. When calculating the first point of the EMA, we may notice that there is no value available to use as the previous EMA. This small problem can be solved by starting the calculation with a simple moving average and continuing on with calculating the EMA.

The primary functions of a moving average is to identify trends and reversals, measure the strength of an asset's momentum and determine potential areas where an asset will find support or resistance. Moving averages are lagging indicator, which means they do not predict new trend, but confirm trends once they have been established.

A stock is deemed to be in an uptrend when the price is above a moving average and the average is sloping upward. Conversely, a trader will use a price below a downward sloping average to confirm a downtrend. Many traders will only consider holding a long position in an asset when the price is trading above a moving average.

In general, short-term momentum can be gauged by looking at moving averages that focus on time periods of 50 days or less. Looking at moving averages that are created with a period of 50 to 100 days is generally regarded as a good measure of medium-term momentum. Finally, any moving average that uses 100 days or more in the calculation can be used as a measure of long-term momentum.

Support, resistence and stoploss can be infered by referring the closet MA below or above the market price. The other factor that is used in short term momentum is the trading volume. The moving averages along with the trading volume can provide a better insight to short term movement.

Markets are moved by their largest participants - I believe this is the single most important principle in short-term trading. Accordingly, I track the presence of large traders by determining how much volume is in the market and how that compares to average. Because volume correlates very highly with volatility, the market's relative volume helps you determine the amount of movement likely at any given time frame--and it helps you handicap the odds of trending vs. remaining slow and range bound.